Cancer drug combo shows promise for Hard-to-Treat bowel cancer
NCT ID NCT02982694
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a combination of two drugs, atezolizumab and bevacizumab, in 46 people with advanced colorectal cancer that had stopped responding to chemotherapy and had a specific genetic feature called MSI-like. The goal was to see if the treatment could shrink tumors. The study was terminated early, but results may help guide future research.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHEMOTHERAPY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fundación Investigación Clínico de Valencia
Valencia, Spain
-
Institut Català d'Oncologia
Barcelona, Spain
-
KU Leuven
Leuven, Belgium
-
Ospedale Niguarda CA Granda
Milan, Italy
-
Second University of Naples
Naples, Italy
-
The Netherlands Cancer Institute
Amsterdam, Netherlands
-
Vall d'Hebron Institute of Oncology
Barcelona, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Can we predict chemo brain before it happens?
- Your gut bacteria might reveal hidden cancer risk
- Can a smart digital program restore sleep for cancer survivors?
- Can a new infusion drug shrink Hard-to-Treat tumors?